Published in Evid Based Complement Alternat Med on June 01, 2008
Immunostimulation-Mediated Anti-tumor Activity of Bamboo (Sasa senanensis) Leaf Extracts Obtained Under 'Vigorous' Condition. Evid Based Complement Alternat Med (2008) 0.89
Antioxidant Activity of Agaricus brasiliensis Basidiocarps on Different Maturation Phases. Braz J Microbiol (2011) 0.87
Ipomoea batatas and Agarics blazei ameliorate diabetic disorders with therapeutic antioxidant potential in streptozotocin-induced diabetic rats. J Clin Biochem Nutr (2011) 0.85
Agaricus subrufescens: A review. Saudi J Biol Sci (2012) 0.85
Antineoplasic activity of Agaricus brasiliensis basidiocarps on different maturation phases. Braz J Microbiol (2009) 0.84
Oral Treatment with Extract of Agaricus blazei Murill Enhanced Th1 Response through Intestinal Epithelial Cells and Suppressed OVA-Sensitized Allergy in Mice. Evid Based Complement Alternat Med (2010) 0.83
Phase I Clinical Study of the Dietary Supplement, Agaricus blazei Murill, in Cancer Patients in Remission. Evid Based Complement Alternat Med (2011) 0.81
Immunomodulating compounds in Basidiomycetes. J Clin Biochem Nutr (2013) 0.78
The effect of enzymatically polymerised polyphenols on CD4 binding and cytokine production in murine splenocytes. PLoS One (2012) 0.78
High molecular weight of polysaccharides from Hericium erinaceus against amyloid beta-induced neurotoxicity. BMC Complement Altern Med (2016) 0.77
Aqueous Extract of Agaricus blazei Murrill Prevents Age-Related Changes in the Myenteric Plexus of the Jejunum in Rats. Evid Based Complement Alternat Med (2015) 0.75
Differences in antioxidant activities of outdoor- and indoor-cultivated Agaricus brasiliensis, and protective effects against carbon tetrachloride-induced acute hepatic injury in mice. BMC Complement Altern Med (2014) 0.75
Effect of mushroom Agaricus blazei on immune response and development of experimental cerebral malaria. Malar J (2015) 0.75
Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat Rev Immunol (2006) 4.84
Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J Clin Invest (2006) 4.45
Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nat Immunol (2006) 4.37
The pharmacological potential of mushrooms. Evid Based Complement Alternat Med (2005) 3.97
Evidence-based Reconstruction of Kampo Medicine: Part I-Is Kampo CAM? Evid Based Complement Alternat Med (2004) 3.62
Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev (2003) 3.15
CAM, eCAM, Bioprospecting: The 21st Century Pyramid. Evid Based Complement Alternat Med (2005) 2.68
Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother (2005) 2.56
Polymorphisms in CD14, mannose-binding lectin, and Toll-like receptor-2 are associated with increased prevalence of infection in critically ill adults. Crit Care Med (2005) 1.99
Bioprospecting: a CAM Frontier. Evid Based Complement Alternat Med (2005) 1.82
Can maitake MD-fraction aid cancer patients? Altern Med Rev (2002) 1.67
Neuroprotection by Brazilian Green Propolis against In vitro and In vivo Ischemic Neuronal Damage. Evid Based Complement Alternat Med (2005) 1.59
The price of success: health care in an aging society. Health Aff (Millwood) (1992) 1.58
The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev (2000) 1.43
CAM and NK Cells. Evid Based Complement Alternat Med (2004) 1.42
Proof of the mysterious efficacy of ginseng: basic and clinical trials: clinical effects of medical ginseng, korean red ginseng: specifically, its anti-stress action for prevention of disease. J Pharmacol Sci (2004) 1.40
Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood (2002) 1.39
CAM and cell fate targeting: molecular and energetic insights into cell growth and differentiation. Evid Based Complement Alternat Med (2005) 1.35
Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet (2006) 1.26
Bioactive components of the traditionally used mushroom Podaxis pistillaris. Evid Based Complement Alternat Med (2006) 1.21
Antitumor beta glucan from the cultured fruit body of Agaricus blazei. Biol Pharm Bull (2001) 1.20
Selective tumoricidal effect of soluble proteoglucan extracted from the basidiomycete, Agaricus blazei Murill, mediated via natural killer cell activation and apoptosis. Cancer Immunol Immunother (1998) 1.16
Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy. Int J Gynecol Cancer (2004) 1.06
Anti-tumor and immunomodulating effects of Pleurotus ostreatus mycelia-derived proteoglycans. Int Immunopharmacol (2006) 1.05
IL-12 Production Induced by Agaricus blazei Fraction H (ABH) Involves Toll-like Receptor (TLR). Evid Based Complement Alternat Med (2004) 1.03
Effect of Maitake (Grifola frondosa) D-Fraction on the activation of NK cells in cancer patients. J Med Food (2003) 1.02
Antioxidant capability of polysaccharides fractionated from submerge-cultured Agaricus blazei mycelia. J Agric Food Chem (2005) 1.01
Modulation of Immune Functions by Foods. Evid Based Complement Alternat Med (2004) 1.01
Suppressing effects of daily oral supplementation of beta-glucan extracted from Agaricus blazei Murill on spontaneous and peritoneal disseminated metastasis in mouse model. J Cancer Res Clin Oncol (2005) 1.00
T-helper type 1/T-helper type 2 balance in malignant pleural effusions compared to tuberculous pleural effusions. Chest (2005) 1.00
Inhibition of IgE-dependent mouse triphasic cutaneous reaction by a boiling water fraction separated from mycelium of Phellinus linteus. Evid Based Complement Alternat Med (2005) 0.99
Effect of a medicinal extract from Agaricus blazei Murill on gene expression in a human monocyte cell line as examined by microarrays and immuno assays. Int Immunopharmacol (2005) 0.95
Antigenotoxicity of Agaricus blazei mushroom organic and aqueous extracts in chromosomal aberration and cytokinesis block micronucleus assays in CHO-k1 and HTC cells. Toxicol In Vitro (2005) 0.95
Partial characterization and immunostimulatory effect of a novel polysaccharide-protein complex extracted from Phellinus linteus. Biosci Biotechnol Biochem (2006) 0.94
Effect of maitake (Grifola frondosa) D-fraction on the control of the T lymph node Th-1/Th-2 proportion. Biol Pharm Bull (2002) 0.94
Maitake extracts and their therapeutic potential. Altern Med Rev (2001) 0.93
An alternative medicine, Agaricus blazei, may have induced severe hepatic dysfunction in cancer patients. Jpn J Clin Oncol (2006) 0.93
Effects of extracts from Brazilian sun-mushroom (Agaricus blazei) on the NK activity and lymphoproliferative responsiveness of Ehrlich tumor-bearing mice. Food Chem Toxicol (2004) 0.91
Delayed Cell Cycle Progression and Apoptosis Induced by Hemicellulase-Treated Agaricus blazei. Evid Based Complement Alternat Med (2006) 0.91
Enhancement of cytotoxicity of NK cells by D-Fraction, a polysaccharide from Grifola frondosa. Oncol Rep (2005) 0.86
In vitro augmentation of natural killer activity and interferon-gamma production in murine spleen cells with Agaricus blazei fruiting body fractions. Biosci Biotechnol Biochem (2005) 0.86
Relationship between dendritic cells and the D-fraction-induced Th-1 dominant response in BALB/c tumor-bearing mice. Cancer Lett (2003) 0.85
Lack of carcinogenicity of agaritine by subcutaneous administration in mice. Mycopathologia (1984) 0.81
Host-mediated antitumor effect of grifolan NMF-5N, a polysaccharide obtained from Grifola frondosa. J Pharmacobiodyn (1987) 0.80
Gene-based drug prescribing: clinical implications of the cytochrome P450 genes. WMJ (2005) 0.80
Antitumor activity of a beta-1,3-glucan obtained from liquid cultured mycelium of Grifola frondosa. J Pharmacobiodyn (1986) 0.79
Agaritine does not mediate the mutagenicity of the edible mushroom Agaricus bisporus. Mutagenesis (1991) 0.79
Measurement of a genotoxic hydrazine, agaritine, and its derivatives by HPLC with fluorescence derivatization in the agaricus mushroom and its products. Chem Pharm Bull (Tokyo) (2006) 0.79
Influence of storage and household processing on the agaritine content of the cultivated Agaricus mushroom. Food Addit Contam (2002) 0.78
Bacterial mutagenicity of extracts of the baked and raw Agaricus bisporus mushroom. In Vivo (1993) 0.77
Stability of agaritine - a natural toxicant of Agaricus mushrooms. Food Addit Contam (2002) 0.77
Agaritine content in processed foods containing the cultivated mushroom (Agaricus bisporus) on the Nordic and the Czech market. Food Addit Contam (1999) 0.77
Wide range of molecular weight distribution of mitogenic substance(s) in the hot water extract of a Chinese herbal medicine, Bupleurum chinense. Biol Pharm Bull (1997) 0.77
Tumor induction by 4-(methyl)benzenediazonium sulfate in mice. In Vivo (1992) 0.77
Antitumor effect of polysaccharide grifolan NMF-5N on syngeneic tumor in mice. J Pharmacobiodyn (1987) 0.77
The mutagenic activity of agaritine--a constituent of the cultivated mushroom Agaricus bisporus--and its derivatives detected with the Salmonella/mammalian microsome assay (Ames Test). Z Lebensm Unters Forsch (1986) 0.77
Analysis of mitogenic substances in Bupleurum chinense by ESR spectroscopy. Biol Pharm Bull (1997) 0.76
Carcinogenic fungal hydrazines. In Vivo (1992) 0.76
Structure-function Relationship of antitumor beta-1,3-glucan obtained from matted mycelium of cultured Grifola frondosa. Chem Pharm Bull (Tokyo) (1985) 0.76
Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78
Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nat Immunol (2006) 4.37
The adaptor protein CARD9 is essential for the activation of myeloid cells through ITAM-associated and Toll-like receptors. Nat Immunol (2007) 4.12
Dectin-2 recognition of alpha-mannans and induction of Th17 cell differentiation is essential for host defense against Candida albicans. Immunity (2010) 3.66
New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer (2002) 3.38
The role of ICOS in the CXCR5+ follicular B helper T cell maintenance in vivo. J Immunol (2005) 3.23
IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci U S A (2010) 3.07
NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J (2003) 2.97
Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol (2002) 2.88
Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood (2002) 2.72
Tumor necrosis factor alpha (TNFalpha) induces the unfolded protein response (UPR) in a reactive oxygen species (ROS)-dependent fashion, and the UPR counteracts ROS accumulation by TNFalpha. J Biol Chem (2005) 2.71
Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J Invest Dermatol (2006) 2.53
Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood (2009) 2.27
An aluminum-activated citrate transporter in barley. Plant Cell Physiol (2007) 2.24
Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest (2002) 2.22
Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med (2006) 2.10
Activation of NK cell cytotoxicity. Mol Immunol (2005) 2.03
TACI attenuates antibody production costimulated by BAFF-R and CD40. Eur J Immunol (2007) 1.94
NKT cells - conductors of tumor immunity? Curr Opin Immunol (2002) 1.94
Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization. J Exp Med (2005) 1.93
Phosphorylation of serine 276 is essential for p65 NF-kappaB subunit-dependent cellular responses. Biochem Biophys Res Commun (2003) 1.91
Simple model for the mechanics of spider webs. Phys Rev Lett (2010) 1.89
Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med (2002) 1.88
TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver. Blood (2004) 1.83
Nature's TRAIL--on a path to cancer immunotherapy. Immunity (2003) 1.77
Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol (2005) 1.76
Cytokine milieu modulates release of thymic stromal lymphopoietin from human keratinocytes stimulated with double-stranded RNA. J Allergy Clin Immunol (2008) 1.74
The human beta-defensins (-1, -2, -3, -4) and cathelicidin LL-37 induce IL-18 secretion through p38 and ERK MAPK activation in primary human keratinocytes. J Immunol (2005) 1.73
Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med (2004) 1.73
Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol (2001) 1.70
Smad3 deficiency attenuates renal fibrosis, inflammation,and apoptosis after unilateral ureteral obstruction. Kidney Int (2004) 1.69
Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responses. Eur J Immunol (2003) 1.69
Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol (2002) 1.65
A semidwarf phenotype of barley uzu results from a nucleotide substitution in the gene encoding a putative brassinosteroid receptor. Plant Physiol (2003) 1.63
Identification of a novel transcriptional activator, BSAC, by a functional cloning to inhibit tumor necrosis factor-induced cell death. J Biol Chem (2002) 1.61
Barley grain with adhering hulls is controlled by an ERF family transcription factor gene regulating a lipid biosynthesis pathway. Proc Natl Acad Sci U S A (2008) 1.60
Genome-wide association study identifies eight new susceptibility loci for atopic dermatitis in the Japanese population. Nat Genet (2012) 1.58
Saccharomyces cerevisiae- and Candida albicans-derived mannan induced production of tumor necrosis factor alpha by human monocytes in a CD14- and Toll-like receptor 4-dependent manner. Microbiol Immunol (2002) 1.57
Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J Immunol (2003) 1.57
TRAIL and its receptors as targets for cancer therapy. Cancer Sci (2004) 1.53
Synergistic effect of antibacterial agents human beta-defensins, cathelicidin LL-37 and lysozyme against Staphylococcus aureus and Escherichia coli. J Dermatol Sci (2005) 1.53
B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J Immunol (2006) 1.52
Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol (2003) 1.50
Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun (2002) 1.48
Development of 5006 full-length CDNAs in barley: a tool for accessing cereal genomics resources. DNA Res (2009) 1.47
Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med (2012) 1.47
Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J Immunol (2009) 1.43
MPO-ANCA induces IL-17 production by activated neutrophils in vitro via classical complement pathway-dependent manner. J Autoimmun (2008) 1.42
Beneficial effects of the Nishino breathing method on immune activity and stress level. J Altern Complement Med (2005) 1.42
CAM and NK Cells. Evid Based Complement Alternat Med (2004) 1.42
Remission of rheumatoid arthritis and potential determinants: a national multi-center cross-sectional survey. Clin Rheumatol (2014) 1.41
Anti-tumor immunity in a model of acute myeloid leukemia. Leuk Lymphoma (2009) 1.39
Differential Al resistance and citrate secretion in barley (Hordeum vulgare L.). Planta (2003) 1.37
Critical role for OX40 ligand in the development of pathogenic Th2 cells in a murine model of asthma. Eur J Immunol (2003) 1.37
Preferential involvement of Tim-3 in the regulation of hepatic CD8+ T cells in murine acute graft-versus-host disease. J Immunol (2006) 1.35
IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood (2002) 1.34
Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol (2008) 1.34
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci U S A (2008) 1.33
Multiple pathways of TWEAK-induced cell death. J Immunol (2002) 1.32
Cutting edge: VacA, a vacuolating cytotoxin of Helicobacter pylori, directly activates mast cells for migration and production of proinflammatory cytokines. J Immunol (2002) 1.30
TIM1 is an endogenous ligand for LMIR5/CD300b: LMIR5 deficiency ameliorates mouse kidney ischemia/reperfusion injury. J Exp Med (2010) 1.29
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. J Natl Cancer Inst (2008) 1.28
Nonredundant roles for CD1d-restricted natural killer T cells and conventional CD4+ T cells in the induction of immunoglobulin E antibodies in response to interleukin 18 treatment of mice. J Exp Med (2003) 1.28
Inducible costimulator-dependent IL-10 production by regulatory T cells specific for self-antigen. Proc Natl Acad Sci U S A (2004) 1.27
BAFF/BLyS can potentiate B-cell selection with the B-cell coreceptor complex. Blood (2003) 1.26
Renal allograft rejection is prevented by adoptive transfer of anergic T cells in nonhuman primates. J Clin Invest (2005) 1.24
Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proc Natl Acad Sci U S A (2008) 1.24
Deoxynucleic acids from Cryptococcus neoformans activate myeloid dendritic cells via a TLR9-dependent pathway. J Immunol (2008) 1.24
Crucial role for autophagy in degranulation of mast cells. J Allergy Clin Immunol (2011) 1.23
FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells. Am J Physiol Renal Physiol (2002) 1.23
Toll-like receptor 9-dependent activation of myeloid dendritic cells by Deoxynucleic acids from Candida albicans. Infect Immun (2009) 1.22
TACI regulates IgA production by APRIL in collaboration with HSPG. Blood (2007) 1.21
An antiapoptotic protein, c-FLIPL, directly binds to MKK7 and inhibits the JNK pathway. EMBO J (2006) 1.20
Combined natural killer T-cell based immunotherapy eradicates established tumors in mice. Cancer Res (2007) 1.19
Characterization of beta-glucan recognition site on C-type lectin, dectin 1. Infect Immun (2004) 1.19
A cell-type-specific requirement for IFN regulatory factor 5 (IRF5) in Fas-induced apoptosis. Proc Natl Acad Sci U S A (2008) 1.19
IL-33-mediated innate response and adaptive immune cells contribute to maximum responses of protease allergen-induced allergic airway inflammation. J Immunol (2013) 1.19
CD1d-restricted natural killer T cells contribute to hepatic inflammation and fibrogenesis in mice. J Hepatol (2010) 1.19
An application of high-throughput SNP genotyping for barley genome mapping and characterization of recombinant chromosome substitution lines. Theor Appl Genet (2009) 1.17
Amelioration of collagen-induced arthritis by blockade of inducible costimulator-B7 homologous protein costimulation. J Immunol (2002) 1.16
The extra domain A of fibronectin stimulates murine mast cells via toll-like receptor 4. J Leukoc Biol (2007) 1.16
Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells. J Immunol (2010) 1.16
Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases. Ann Surg Oncol (2013) 1.16
Activation of cyclin D1-kinase in murine fibroblasts lacking both p21(Cip1) and p27(Kip1). Oncogene (2002) 1.15
Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer. Jpn J Clin Oncol (2012) 1.15
Activation of TGF-beta/Smad2 signaling is associated with airway remodeling in asthma. J Allergy Clin Immunol (2002) 1.15
The receptor LMIR3 negatively regulates mast cell activation and allergic responses by binding to extracellular ceramide. Immunity (2012) 1.15
The plasminogen fibrinolytic pathway is required for hematopoietic regeneration. Cell Stem Cell (2007) 1.15
Involvement of TNF-like weak inducer of apoptosis in the pathogenesis of collagen-induced arthritis. J Immunol (2006) 1.14
Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules. J Immunol (2010) 1.14
Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection. Infect Immun (2005) 1.13
Scavenger receptor A (SR-A) is required for LPS-induced TLR4 mediated NF-κB activation in macrophages. Biochim Biophys Acta (2012) 1.12
Delta-like 1 is essential for the maintenance of marginal zone B cells in normal mice but not in autoimmune mice. Int Immunol (2008) 1.12